Abstract
The mechanism for the chemoresistance of cancer cells is quite complicated. Most of the anti-cancer drugs are known to induce apoptosis in cancer cells, as well as in normal cells, in part by the activation of the p53 pathway. p53 is often referred to as the 'guardian of the genome' and is one of the most investigated tumor suppressor genes. A majority of human tumors harbor p53 mutations which can influence the effect of chemotherapy. Thus pre-therapeutic evaluation of the p53 gene can be extremely informative for patients with diverse malignancies. In this mini review, we introduce a p53 functional analysis system in mammalian cells, which can identify different types of p53 abnormalities, such as loss of function, dominant negative function, or gain of oncogenic function. The kinetic analysis of mutated-p53 may help to determine the therapeutic strategy in the individual patients with several malignancies. Furthermore, detailed information on the mutated p53 gene in cancer cells might provide useful suggestions for developing new anti-cancer drugs.
Keywords: Chemoresistance, head and neck cancer, oncogenic mutation, p53, p53-target genes, tumor suppressor gene.
Graphical Abstract
Current Signal Transduction Therapy
Title:Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Volume: 11 Issue: 1
Author(s): Daisuke Uchida, Hitoshi Kawamata, Fujiyuki Inaba, Ichio Fukasawa and Takahiro Fujimori
Affiliation:
Keywords: Chemoresistance, head and neck cancer, oncogenic mutation, p53, p53-target genes, tumor suppressor gene.
Abstract: The mechanism for the chemoresistance of cancer cells is quite complicated. Most of the anti-cancer drugs are known to induce apoptosis in cancer cells, as well as in normal cells, in part by the activation of the p53 pathway. p53 is often referred to as the 'guardian of the genome' and is one of the most investigated tumor suppressor genes. A majority of human tumors harbor p53 mutations which can influence the effect of chemotherapy. Thus pre-therapeutic evaluation of the p53 gene can be extremely informative for patients with diverse malignancies. In this mini review, we introduce a p53 functional analysis system in mammalian cells, which can identify different types of p53 abnormalities, such as loss of function, dominant negative function, or gain of oncogenic function. The kinetic analysis of mutated-p53 may help to determine the therapeutic strategy in the individual patients with several malignancies. Furthermore, detailed information on the mutated p53 gene in cancer cells might provide useful suggestions for developing new anti-cancer drugs.
Export Options
About this article
Cite this article as:
Uchida Daisuke, Kawamata Hitoshi, Inaba Fujiyuki, Fukasawa Ichio and Fujimori Takahiro, Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene, Current Signal Transduction Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574362411999160606163438
DOI https://dx.doi.org/10.2174/1574362411999160606163438 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy VEGF Inhibitors in Cancer Therapy
Current Pharmaceutical Design Systemic Delivery of Curcumin: 21st Century Solutions for an Ancient Conundrum
Current Drug Discovery Technologies A Comparison Between Bisphosphonates and Other Treatments for Osteoporosis
Current Pharmaceutical Design Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets A Review of Fish Lectins
Current Protein & Peptide Science Perspectives on Adipose-Derived Stem/Stromal Cells as Potential Treatment for Scarred Vocal Folds: Opportunity and Challenges
Current Stem Cell Research & Therapy Feasibility of Margin Reduction for Level II and III Planning Target Volume in Head-and-Neck Image-Guided Radiotherapy – Dosimetric Assessment via A Deformable Image Registration Framework
Current Cancer Therapy Reviews Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Nanoparticulate Drug Delivery Sytem for Cancer Therapy: Oppourtunities and Challenges
Recent Patents on Nanomedicine Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Adhesion Dependent Signalling in the Tumour Microenvironment: The Future of Drug Targetting
Current Pharmaceutical Design Targeted Therapy for Advanced Renal Cell Cancer: Cytokines and Beyond
Current Pharmaceutical Design γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug Targets miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine Smoking and Endothelial Progenitor Cells: A Revision of Literature
Current Pharmaceutical Design Multiple Functions of Rad9 for Preserving Genomic Integrity
Current Genomics Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Novel Artemisinin-Derived Dimers: Synthesis and Evaluation of Anti-cancer Activities
Letters in Drug Design & Discovery Expression and Characterisation of Recombinant Molecules in Transgenic Soybean
Current Pharmaceutical Design